-Yselty® for uterine fibroids: US New Drug Application submission planned in Q3:21; European marketing approval recommendation anticipated in Q4:21- -Yselty®…
Category: Press release
The press releases from ObsEva
ObsEva appoints Clive Bertram as Chief Commercial Officer
GENEVA, Switzerland and BOSTON, MA – May 6, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing…
ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain
– EDELWEISS 3 trial of Yselty® expected to report topline data as planned in Q4:21- GENEVA, Switzerland and BOSTON, MA –…
ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 – May 2, 2021
GENEVA, Switzerland and BOSTON, MA – April 30, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN) a biopharmaceutical company…
ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants
-Long-term follow-up study to evaluate bone mineral density in women completing at least 20 weeks of treatment in Phase 3…
ObsEva Annual General Meeting 2021
Geneva, Switzerland and Boston, MA – April 22, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve…
ObsEva Announces Year End 2020 Financial Results and Business Update
-Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21- -Yselty® for…
ObsEva to Present at the H.C. Wainwright Global Life Sciences Conference
Geneva, Switzerland and Boston, MA – March 3, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company…
ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
Geneva, Switzerland and Boston, MA – February 17, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares
Geneva, Switzerland and Boston, MA – Thursday 11 February, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss…